Paralel Advisors LLC Raises Stock Position in United Therapeutics Co. (NASDAQ:UTHR)

Paralel Advisors LLC boosted its position in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 10.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 10,929 shares of the biotechnology company's stock after acquiring an additional 992 shares during the period. United Therapeutics accounts for about 0.2% of Paralel Advisors LLC's holdings, making the stock its 29th biggest position. Paralel Advisors LLC's holdings in United Therapeutics were worth $3,856,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Wealthfront Advisers LLC grew its stake in United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after buying an additional 18,313,424 shares in the last quarter. Norges Bank bought a new position in United Therapeutics in the fourth quarter valued at $151,764,000. FMR LLC raised its position in United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock valued at $519,170,000 after purchasing an additional 393,777 shares in the last quarter. Thrivent Financial for Lutherans lifted its stake in United Therapeutics by 1,325.5% during the fourth quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company's stock worth $72,085,000 after purchasing an additional 189,967 shares during the last quarter. Finally, AustralianSuper Pty Ltd lifted its stake in United Therapeutics by 577.1% during the fourth quarter. AustralianSuper Pty Ltd now owns 189,780 shares of the biotechnology company's stock worth $66,962,000 after purchasing an additional 161,751 shares during the last quarter. Institutional investors own 94.08% of the company's stock.

Insider Activity at United Therapeutics

In other United Therapeutics news, COO Michael Benkowitz sold 10,000 shares of the stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $364.91, for a total value of $3,649,100.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at approximately $940,373.07. This represents a 79.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Paul A. Mahon sold 11,000 shares of the business's stock in a transaction on Thursday, April 3rd. The shares were sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the sale, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. This trade represents a 23.02 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 77,500 shares of company stock worth $26,994,480 over the last 90 days. 11.90% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on UTHR shares. StockNews.com downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a research report on Thursday, February 27th. UBS Group boosted their price objective on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a "buy" rating in a report on Wednesday, January 8th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $425.00 target price on shares of United Therapeutics in a report on Thursday, February 27th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $388.25.

United Therapeutics Price Performance

UTHR traded down $1.51 during midday trading on Tuesday, reaching $282.80. 274,562 shares of the company's stock traded hands, compared to its average volume of 452,684. The stock has a market capitalization of $12.70 billion, a price-to-earnings ratio of 12.42, a P/E/G ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 52 week low of $230.39 and a 52 week high of $417.82. The firm has a fifty day moving average of $321.83 and a two-hundred day moving average of $350.58.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping analysts' consensus estimates of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter last year, the firm posted $4.36 earnings per share. Sell-side analysts forecast that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.